What to Measure in Autism Drug Trials

Journal of Autism and Developmental Disorders

Volumn 31, Issue 3, 2001, Pages 361-362

  Roseman, Bruce ^a   Schneider, Elaine ^a   Crimmins, Daniel ^a   Bostwick, Howard ^a   Visintainer, Paul ^a   Jaskow, Peter A ^a   Accardo, Pasquale ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SECRETIN; GASTROINTESTINAL AGENT;

AUTISM; CAROL PRUTTING PRAGMATIC LANGUAGE SCALE; CHILD; CHILD BEHAVIOR; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG RESEARCH; FEMALE; HUMAN; LANGUAGE; LETTER; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RATING SCALE; TREATMENT OUTCOME; PRESCHOOL CHILD; QUESTIONNAIRE;

AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; QUESTIONNAIRES; SECRETIN;

EID: 0035376249     PISSN: 01623257     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1017339106682     Document Type: Letter

References (4)

1. Chez, M. G., Buchanan, C. P., Bagan, B. T., Hammer, M. S., McCarthy, K. S., Ovrutskaya, I., Nowinski, C. V., & Cohen, Z. S. (2000). Secretin and autism: A two-part clinical investigation. Journal of Autism and Developmental Disorders, 30, 87-94.
2. Horvath, K., Stefanatos, G., Sokolski, K. N., Wachtel, R. C., Nabors, L., & Tildon, J. T. (1998). Improved social and language skills after secretin administration in patients with autistics spectrum disorders. Journal of the Association for Academic Minority Physicians, 9, 9-15.
3. Lightdale, J. R., Hayer, C., Duer, A., Lind-White, C., Siegel, B., Elliott, G. R., & Heyman, M. B. (2000). Analysis of formal language testing following an open-label trial of secretin in children with autism. Pediatric Research, 47, 29A (Abstr. 169).
4. Sandler, A. D., Sutton, K. A., DeWeese, J., Girardi. M. A., Sheppard, V., & Bodfish, J. W. (1999). Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. New England Journal of Medicine, 341, 1801-1806.